Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | -119.29 Thousand USD | -135.86% |
| 2021 | 332.67 Thousand USD | -63.6% |
| 2020 | 913.96 Thousand USD | 4481.05% |
| 2019 | 19.95 Thousand USD | -91.17% |
| 2018 | 225.88 Thousand USD | -87.5% |
| 2017 | 1.8 Million USD | -90.82% |
| 2016 | 19.67 Million USD | 71.15% |
| 2015 | 11.49 Million USD | 145.15% |
| 2014 | 4.68 Million USD | 487.69% |
| 2013 | 797.81 Thousand USD | 913.25% |
| 2012 | 78.73 Thousand USD | -86.83% |
| 2011 | 597.72 Thousand USD | -92.02% |
| 2010 | 7.49 Million USD | 17.4% |
| 2009 | 6.38 Million USD | 30.91% |
| 2008 | 4.87 Million USD | 23.75% |
| 2007 | 3.94 Million USD | 15.24% |
| 2006 | 3.41 Million USD | -3.51% |
| 2005 | 3.54 Million USD | -1.79% |
| 2004 | 3.6 Million USD | 6.58% |
| 2003 | 3.38 Million USD | 31.72% |
| 2002 | 2.56 Million USD | -19.65% |
| 2001 | 3.19 Million USD | -37.03% |
| 2000 | 5.07 Million USD | -7.5% |
| 1999 | 5.49 Million USD | 23.98% |
| 1998 | 4.42 Million USD | 24.68% |
| 1997 | 3.55 Million USD | 618.47% |
| 1996 | 494.41 Thousand USD | -1.12% |
| 1995 | 500 Thousand USD | -37.5% |
| 1994 | 800 Thousand USD | 113.79% |
| 1993 | -5.8 Million USD | 0.0% |
| 1992 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | -36.37 Thousand USD | 0.47% |
| 2023 Q1 | -36.55 Thousand USD | 26.05% |
| 2023 Q3 | -36.03 Thousand USD | 0.96% |
| 2022 Q3 | -126.92 Thousand USD | -2199.27% |
| 2022 Q4 | -49.42 Thousand USD | 61.06% |
| 2022 FY | -119.29 Thousand USD | -135.86% |
| 2022 Q1 | -53.23 Thousand USD | -3819.88% |
| 2022 Q2 | 6046.00 USD | 111.36% |
| 2021 Q3 | 47.81 Thousand USD | -81.68% |
| 2021 Q4 | -1358.00 USD | -102.84% |
| 2021 Q2 | 261.04 Thousand USD | 110.97% |
| 2021 FY | 332.67 Thousand USD | -63.6% |
| 2021 Q1 | 123.73 Thousand USD | -43.56% |
| 2020 Q4 | 219.25 Thousand USD | 3176.8% |
| 2020 FY | 913.96 Thousand USD | 4481.05% |
| 2020 Q1 | 14.61 Thousand USD | 468.12% |
| 2020 Q2 | 8563.00 USD | -41.4% |
| 2020 Q3 | 6691.00 USD | -21.86% |
| 2019 Q1 | 91.43 Thousand USD | 648.52% |
| 2019 FY | 19.95 Thousand USD | -91.17% |
| 2019 Q4 | 2572.00 USD | -45.28% |
| 2019 Q3 | 4700.00 USD | -69.98% |
| 2019 Q2 | 15.65 Thousand USD | -82.88% |
| 2018 FY | 225.88 Thousand USD | -87.5% |
| 2018 Q4 | 12.21 Thousand USD | 177.36% |
| 2018 Q3 | -15.78 Thousand USD | -106.9% |
| 2018 Q2 | 228.98 Thousand USD | 47904.61% |
| 2018 Q1 | 477.00 USD | -99.88% |
| 2017 Q3 | 223.66 Thousand USD | -63.43% |
| 2017 Q4 | 391.48 Thousand USD | 75.03% |
| 2017 Q2 | 611.59 Thousand USD | 5.44% |
| 2017 FY | 1.8 Million USD | -90.82% |
| 2017 Q1 | 580.03 Thousand USD | -81.14% |
| 2016 Q2 | 4.83 Million USD | 15.43% |
| 2016 FY | 19.67 Million USD | 71.15% |
| 2016 Q4 | 3.07 Million USD | -59.39% |
| 2016 Q3 | 7.57 Million USD | 56.72% |
| 2016 Q1 | 4.18 Million USD | 10.83% |
| 2015 FY | 11.49 Million USD | 145.15% |
| 2015 Q4 | 3.77 Million USD | 7.29% |
| 2015 Q2 | 2.53 Million USD | 52.78% |
| 2015 Q3 | 3.52 Million USD | 38.91% |
| 2015 Q1 | 1.65 Million USD | -11.91% |
| 2014 Q3 | 1.44 Million USD | 79.33% |
| 2014 Q2 | 804.19 Thousand USD | 43.97% |
| 2014 FY | 4.68 Million USD | 487.69% |
| 2014 Q1 | 558.58 Thousand USD | 45.84% |
| 2014 Q4 | 1.88 Million USD | 30.62% |
| 2013 FY | 797.81 Thousand USD | 913.25% |
| 2013 Q4 | 383.02 Thousand USD | 17.87% |
| 2013 Q2 | 89.83 Thousand USD | 0.0% |
| 2013 Q3 | 324.95 Thousand USD | 261.7% |
| 2013 Q1 | - USD | -100.0% |
| 2012 FY | 78.73 Thousand USD | -86.83% |
| 2012 Q4 | 6807.00 USD | -97.99% |
| 2012 Q3 | 339 Thousand USD | 465.0% |
| 2012 Q2 | 60 Thousand USD | 402.89% |
| 2012 Q1 | 11.93 Thousand USD | 100.15% |
| 2011 Q2 | 2.19 Million USD | 5.26% |
| 2011 FY | 597.72 Thousand USD | -92.02% |
| 2011 Q4 | -8.04 Million USD | -3248.93% |
| 2011 Q3 | 255.63 Thousand USD | -88.34% |
| 2011 Q1 | 2.08 Million USD | -9.26% |
| 2010 Q2 | 1.72 Million USD | -3.73% |
| 2010 Q3 | 1.67 Million USD | -2.91% |
| 2010 Q4 | 2.29 Million USD | 36.91% |
| 2010 FY | 7.49 Million USD | 17.4% |
| 2010 Q1 | 1.79 Million USD | 9.39% |
| 2009 FY | 6.38 Million USD | 30.91% |
| 2009 Q4 | 1.64 Million USD | -1.17% |
| 2009 Q2 | 1.24 Million USD | -33.59% |
| 2009 Q3 | 1.65 Million USD | 33.17% |
| 2009 Q1 | 1.87 Million USD | 44.63% |
| 2008 Q3 | 1.1 Million USD | -17.87% |
| 2008 Q2 | 1.34 Million USD | 20.09% |
| 2008 Q1 | 1.12 Million USD | 10.07% |
| 2008 Q4 | 1.29 Million USD | 17.16% |
| 2008 FY | 4.87 Million USD | 23.75% |
| 2007 FY | 3.94 Million USD | 15.24% |
| 2007 Q4 | 1.02 Million USD | -11.19% |
| 2007 Q3 | 1.14 Million USD | 40.49% |
| 2007 Q2 | 817.58 Thousand USD | -14.28% |
| 2007 Q1 | 953.82 Thousand USD | -2.7% |
| 2006 Q1 | 1.05 Million USD | 34.51% |
| 2006 FY | 3.41 Million USD | -3.51% |
| 2006 Q3 | 554.76 Thousand USD | -33.42% |
| 2006 Q2 | 833.22 Thousand USD | -20.7% |
| 2006 Q4 | 980.25 Thousand USD | 76.7% |
| 2005 FY | 3.54 Million USD | -1.79% |
| 2005 Q2 | 1.05 Million USD | 17.29% |
| 2005 Q4 | 781.11 Thousand USD | -2.47% |
| 2005 Q3 | 800.93 Thousand USD | -24.34% |
| 2005 Q1 | 902.56 Thousand USD | 50.15% |
| 2004 Q1 | 885.47 Thousand USD | 0.29% |
| 2004 Q2 | 1.03 Million USD | 17.37% |
| 2004 Q3 | 1.08 Million USD | 4.09% |
| 2004 Q4 | 601.12 Thousand USD | -44.43% |
| 2004 FY | 3.6 Million USD | 6.58% |
| 2003 Q1 | 699.97 Thousand USD | -39.28% |
| 2003 FY | 3.38 Million USD | 31.72% |
| 2003 Q4 | 882.88 Thousand USD | 28.31% |
| 2003 Q3 | 688.07 Thousand USD | -38.23% |
| 2003 Q2 | 1.11 Million USD | 59.15% |
| 2002 Q2 | 559.19 Thousand USD | -1.34% |
| 2002 Q1 | 566.79 Thousand USD | -42.66% |
| 2002 FY | 2.56 Million USD | -19.65% |
| 2002 Q4 | 1.15 Million USD | 296.13% |
| 2002 Q3 | 291 Thousand USD | -47.96% |
| 2001 Q3 | 702.45 Thousand USD | -15.99% |
| 2001 FY | 3.19 Million USD | -37.03% |
| 2001 Q2 | 836.16 Thousand USD | 24.57% |
| 2001 Q1 | 671.22 Thousand USD | -60.5% |
| 2001 Q4 | 988.42 Thousand USD | 40.71% |
| 2000 Q4 | 1.69 Million USD | 55.3% |
| 2000 Q2 | 1.26 Million USD | 24.46% |
| 2000 Q1 | 1.01 Million USD | -30.26% |
| 2000 FY | 5.07 Million USD | -7.5% |
| 2000 Q3 | 1.09 Million USD | -13.65% |
| 1999 Q3 | 930 Thousand USD | -22.5% |
| 1999 Q2 | 1.2 Million USD | -7.69% |
| 1999 Q4 | 1.46 Million USD | 56.99% |
| 1999 Q1 | 1.3 Million USD | -20.18% |
| 1999 FY | 5.49 Million USD | 23.98% |
| 1998 Q4 | 1.62 Million USD | 35.73% |
| 1998 Q1 | 700 Thousand USD | -33.47% |
| 1998 FY | 4.42 Million USD | 24.68% |
| 1998 Q2 | 1 Million USD | 42.86% |
| 1998 Q3 | 1.2 Million USD | 20.0% |
| 1997 Q2 | 900 Thousand USD | 50.0% |
| 1997 Q4 | 1.05 Million USD | 5.22% |
| 1997 Q3 | 1 Million USD | 11.11% |
| 1997 FY | 3.55 Million USD | 618.47% |
| 1997 Q1 | 600 Thousand USD | 208.62% |
| 1996 FY | 494.41 Thousand USD | -1.12% |
| 1996 Q4 | 194.41 Thousand USD | 94.41% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q1 | - USD | -100.0% |
| 1995 Q3 | - USD | -100.0% |
| 1995 Q4 | 200 Thousand USD | 0.0% |
| 1995 FY | 500 Thousand USD | -37.5% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1995 Q1 | 100 Thousand USD | -83.33% |
| 1994 FY | 800 Thousand USD | 113.79% |
| 1994 Q1 | -1.6 Million USD | 0.0% |
| 1994 Q2 | -1.3 Million USD | 18.75% |
| 1994 Q3 | 100 Thousand USD | 107.69% |
| 1994 Q4 | 600 Thousand USD | 500.0% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 FY | -5.8 Million USD | 0.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q3 | 100 Thousand USD | 0.0% |
| 1992 Q4 | - USD | -100.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | 174.559% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 52.282% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 99.592% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 83.174% |
| Azitra, Inc. | 260.45 Thousand USD | 145.803% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 116.056% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | 95.375% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | 90.502% |
| CEL-SCI Corporation | -3.95 Million USD | 96.986% |
| iBio, Inc. | -1.02 Million USD | 88.361% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 101.442% |
| MAIA Biotechnology, Inc. | - USD | Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 99.109% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 101.511% |
| NanoViricides, Inc. | -759.01 Thousand USD | 84.283% |
| Oragenics, Inc. | -15.45 Million USD | 99.228% |
| BiomX Inc. | -1.22 Million USD | 90.285% |
| BiomX Inc. | -1.22 Million USD | 90.285% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 100.281% |
| Palatin Technologies, Inc. | 4.39 Million USD | 102.716% |
| Scorpius Holdings, Inc. | -2.21 Million USD | 94.618% |